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Introduction
The cells and pathways surrounding the process of inflam-
mation are incredibly complex, which in turn has estab-
lished a prolific platform for research that has revealed of a 
wide range of potential new drug targets. This is particu-
larly true in the case of macrophages, which are key players 
in the innate immune response and exhibit great plasticity in 
response to various environmental stimuli. Macrophage 
stimulation results in distinct phenotypic changes ranging 
from pro- to anti-inflammatory activation states, as well as 
many in between.1 Several chronic inflammatory and auto-
immune diseases, such as Crohn’s disease and rheumatoid 
arthritis, have been implicated in the switch of innate mac-
rophages to a proinflammatory state. These effects can be 
countered by interleukin-10 (IL-10), a potent repressor of 
proinflammatory cytokine production.2,3 Innovative thera-
peutic approaches targeting these diseases could exploit this 
macrophage plasticity in an attempt to reduce the inflam-
matory response and alleviate patient symptoms.
Current work in this field has highlighted that one or 
potentially all three isoforms of salt-inducible kinases 
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Abstract
Matrix-assisted laser desorption/ionization time-of-flight (MALDI TOF) mass spectrometry has become a promising 
alternative for high-throughput drug discovery as new instruments offer high speed, flexibility and sensitivity, and the 
ability to measure physiological substrates label free. Here we developed and applied high-throughput MALDI TOF mass 
spectrometry to identify inhibitors of the salt-inducible kinase (SIK) family, which are interesting drug targets in the field of 
inflammatory disease as they control production of the anti-inflammatory cytokine interleukin-10 (IL-10) in macrophages. 
Using peptide substrates in in vitro kinase assays, we can show that hit identification of the MALDI TOF kinase assay 
correlates with indirect ADP-Hunter kinase assays. Moreover, we can show that both techniques generate comparable 
IC50 data for a number of hit compounds and known inhibitors of SIK kinases. We further take these inhibitors to 
a fluorescence-based cellular assay using the SIK activity-dependent translocation of CRTC3 into the nucleus, thereby 
providing a complete assay pipeline for the identification of SIK kinase inhibitors in vitro and in cells. Our data demonstrate 
that MALDI TOF mass spectrometry is fully applicable to high-throughput kinase screening, providing label-free data 
comparable to that of current high-throughput fluorescence assays.
Keywords
MALDI TOF, mass spectrometry, salt inducible kinases, kinase, high-throughput screen, inflammation, drug discovery, 
macrophage, interleukin-10
1194 SLAS Discovery 22(10)
(SIKs) play a major regulatory role in macrophage pheno-
type switching by negatively regulating the production of 
the anti-inflammatory cytokine IL-10.4–6 SIKs belong to the 
serine/threonine protein kinase family and have been impli-
cated in a wide range of biological processes such as insulin 
signal transduction and metabolic regulation, but their 
importance in the inflammatory response is best estab-
lished.7,8 Previously, it was shown that prostaglandins acti-
vate protein kinase A (PKA), which prevents SIKs from 
phosphorylating its substrates in cells. Subsequent dephos-
phorylation of the SIK target CREB-related transcriptional 
coactivator 3 (CRTC3) at Ser62, Ser162, Ser329, and 
Ser370 leads to its nuclear translocation promoting CREB-
dependent gene transcription and increased IL-10 produc-
tion.6,9,10 Consequently, small-molecule inhibitors affecting 
SIKs have been shown to increase IL-10 production, 
thereby switching macrophages to an anti-inflammatory 
phenotype.4,11,12 This suggests that SIKs are attractive drug 
targets to combat chronic inflammatory diseases.13 As 
kinases are dysregulated in many diseases and are consid-
ered excellent drug targets,14 methods for kinase profiling 
and screening are well established. However, current non-
cellular methods of kinase profiling are often indirect, mea-
suring fluorescence of labeled nonphysiological peptides or 
adenosine diphosphate (ADP), and/or inclusion of coupling 
enzymes, or, if direct, require the incorporation of 33P 
through radiolabeled adenosine triphosphate (ATP), which 
has become unpopular for safety reasons.
A previously very low-throughput technology that could 
rival these methods in the future is mass spectrometry (MS), 
which is frequently used to identify and characterize biomole-
cules. Recent developments based on electrospray ionization 
(ESI) such as RapidFire15,16 or acoustic loading of the mass 
spectrometer17 have substantially improved the throughput in 
mass spectrometry–based label-free systems, but ESI suffers 
from the need to clean up samples due to the low tolerance for 
salts and other compounds. Matrix-assisted laser desorption/
ionization (MALDI)18 mass spectrometry, on the other hand, is 
tolerant to a number of standard buffer components19 and has 
rapidly become more popular in the field of drug discovery 
due to requiring very small sample quantities, minimal sample 
cleanup, and, most important for high-throughput screening 
(HTS), very high speed. Historically, MALDI is the most vali-
dated and robust surface ionization method whereby the ana-
lyte is mixed with a matrix, typically low molecular weight 
organic acids, and then co-crystalized on a metal target.20 Laser 
irradiation of the dried droplet facilitates proton transfer from 
the matrix to the analyte, thus ionizing the analyte and allow-
ing MS detection. Designed to be a soft ionization method spe-
cifically suitable for quantitatively detecting biomolecules in a 
single charge state, MALDI is particularly suitable for cou-
pling to time-of-flight mass spectrometers (TOF-MS). MALDI 
TOF technology has therefore already found traction in the 
HTS field with its application to label-free screening 
for inhibitors for deubiquitinating enzymes by measuring the 
formation of monoubiquitin, an 8.5-kDa protein, as well as for 
a histone demethylase and an acetylcholinesterase, where it 
was also shown that this technology can be expanded to an 
ultra-HTS platform.21,22
Here we describe the development and validation of a 
novel MALDI TOF assay targeted at screening compounds 
against the kinase SIK2, which has previously been indi-
cated as being an interesting therapeutic target. We compare 
our MALDI TOF data from a small compound screen to a 
conventional ADP fluorescence assay, showing good cor-
relation between these methods for the positive hits. Finally, 
we apply a fluorescence-based assay to further characterize 
SIK kinase inhibitor candidates in cells.
Materials and Methods
Materials
DMSO, α-cyano-4-hydroxycinnamic acid (CHCA), trifluoro-
acetic acid (TFA), magnesium acetate, Tris-HCl, dithiothreitol 
(DTT), ATP, ammonium citrate dibasic, high-performance liq-
uid chromatography (HPLC)–grade water, HPLC-grade 
acetonitrile, and HPLC-grade isopropanol were purchased 
from Sigma-Aldrich (St. Louis, MO). Small-molecule inhibi-
tors staurosporine, HG-9-91-01, MRT199665, MRT67307, 
KIN112, human full-length SIK2 (expressed in insect cells), 
and the peptide substrates CHKtide (KKKVSRSGLYRS- 
PSMPENLNRPR) and NUAK peptide (ALNRTSSDSA- 
LHRRR) were provided or produced in-house and are available 
to request from our reagent’s website (https://mrcppureagents 
.dundee.ac.uk/). 1536 MTP AnchorChip targets and peptide 
calibration standard II were purchased from Bruker Daltonics 
(Bremen, Germany).
Preparation of Plates for Screening
For single-concentration screening, 15 nL (MALDI TOF 
assay) or 24 nL (ADP Hunter assay; DiscoverX, Fremont, 
CA, USA, UK) of a 10-mM compound solution in DMSO 
was transferred into 384-well HiBase, nonbinding microti-
ter plates (Greiner, Stonehouse, UK), using an Echo 550 
acoustic dispenser (Labcyte, San Jose, CA, USA), to give a 
final screening concentration of 30 µM. Staurosporine at 10 
µM was used as a positive control in column 24, with col-
umn 23 containing only DMSO as the negative control. The 
Dundee Drug Discovery Unit (DDU) small-molecule kinase 
library contains 2648 commercially available ATP mimetics 
describing a diverse region of kinase pharmacophore space.
SIK ADP Hunter Assay
The ADP Hunter technology (DiscoverX) is a coupled 
enzyme assay that detects the production of the resorufin 
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fluorophore as a downstream consequence of the conver-
sion of ATP to ADP. It therefore provides a generic high-
throughput assay for the measurement of kinase enzyme 
activity. Screening of full-length GST-tagged human SIK2 
was performed using CHKtide as a substrate peptide. 
Compounds were stamped into 384-well, low-volume, 
black-wall, assay plates (Greiner Bio-one, Stonehouse, 
UK) as described above. The assay window was defined by 
addition of DMSO in the presence (no effect) or absence 
of enzyme (maximum effect) to defined control wells. 
Using a Wellmate liquid dispenser (Thermo Scientific, 
Hemel-Hempstead, UK), 4 µL of a 2× enzyme solution 
(ADP Hunter Plus assay buffer, 1 mM DTT, enzyme) was 
dispensed into all wells and preincubated for 20 min at 
room temperature. The assay enzyme reaction was initiated 
by the addition of 4 µL of a 2× substrate solution (ADP 
Hunter Plus assay buffer, 100 µM CHKtide, 200 µM ATP 
Gold) such that the final assay concentration of SIK2 was 
10 nM. Assay plates were incubated for 30 min at room 
temperature, after which the reaction was stopped by the 
addition of 4 µL ADP Hunter Plus Reagent A and 8 µL ADP 
Hunter Plus Reagent B. Following a further incubation for 30 
min at room temperature, resorufin-elicited fluorescence was 
measured (ex 550 nm; em 595 nm) using a PHERAstar FS 
(BMG Labtech, Aylesbury, UK).
SIK MALDI TOF Assay
In this assay, the appearance of phosphorylated CHKtide 
product at m/z 2779.47 was monitored with respect to the 
CHKtide substrate at m/z 2700.47 using MALDI TOF mass 
spectrometry.
Screening assays were performed with an XRD-384 
Automated Reagent Dispenser (Fluid, Nether Alderley, 
UK) by dispensing 3 µL of freshly prepared assay buffer (50 
mM Tris/HCl, 10 mM magnesium acetate, 2 mM DTT, pH 
7.5) and 1 µL of 15 nM SIK2 prepared in assay buffer onto 
prepared compound plates followed by a 30-min incubation 
at 30 °C. The reaction was then initiated by addition of 1 µL 
substrate solution containing a mixture of CHKtide and 
ATP to a final concentration of 1 µM and 100 µM, respec-
tively. Plates were then returned to incubation at 30 °C for 
30 min before being quenched by addition of 1.2 µL of TFA 
to a final concentration of 2%.
MALDI MS Target Spotting
First, 9.04 mg dibasic ammonium citrate was dissolved in 1 
mL HPLC-grade water and vortexed to create a 40-mM 
solution. Then, 10 mg CHCA was weighed out and pre-
pared to a final volume of 1 mL in 50% HPLC-grade ACN 
and 50% water (v/v), 0.1% TFA, and 10 mM dibasic ammo-
nium citrate and was prepared and placed on a shaker for 30 
min to aid dissolution before use.
Quenched samples and freshly prepared CHCA matrix 
solution were mixed in a 1:1 ratio (v/v) with a Mosquito 
nanoliter dispenser in an LVSD plate (TTP Labtech, 
Melbourn, Hertfordshire, UK) and spotted with the dried 
droplet technique in 200-nL aliquots onto 1536-MTP 
AnchorChip targets (Bruker Daltonics). Each sample 
was spotted in duplicate and the spotted targets allowed 
to air dry before MALDI-MS analysis.
MTP AnchorChip targets were cleaned before each use 
by sonication in HPLC-grade isopropanol for 2 min, fol-
lowed by sonication in 30% acetonitrile and 0.1% TFA for 
2 min. Targets were then placed in a clean room and allowed 
to ambient dry before use.
MALDI-MS Analysis
A RapifleX MALDI TOF/TOF mass spectrometer (Bruker 
Daltonics) equipped with a Smartbeam 3D laser was used 
in positive ion mode with Compass 2.0 control for all 
data acquisition. Samples were run in automatic mode 
(AutoXecute; Bruker Daltonics), acquiring 5000 shots at a 
10-kHz frequency per spot in a random walk on spot laser 
ablation pattern and M5 Smartbeam Parameter at a 25-µm × 
25-µm scan range. Ionization was achieved using a fixed 
laser power of 70% (laser attenuator offset 7%, range 30%) 
and detected by the FlashDetector, Bruker, Bremen, 
Germany at a detector gain of ×2 in the 2500 to 2800 m/z 
mass range. Samples were analyzed in Reflector mode with 
optimized voltages for reflector 1 (20.82 kV), reflector 2 
(1.085 kV), and reflector 3 (8.8 kV), ion sources (ion source 
1, 20 kV, PIE 2.66 kV), lens (11.3 kV), and a pulsed ion 
extraction of 200 ns. A novel 10-bit digitizer was used at a 
sampling rate of 5.00 GS/s.
Spectra were accumulated with FlexControl software 
(v4.0) and processed using FlexAnalysis software (v4.0) 
(Bruker Daltonics). Peaks were centroid detected with a 
signal-to-noise threshold of 6.00 to detect only the intense 
peaks before being processed with a Savitzky-Golay smooth-
ing algorithm (0.05 m/z width, one cycle) and “TopHat” base-
line subtraction. External calibration was performed before 
each new target in Cubic Enhanced mode with Pepmix II 
calibrant (Bruker Daltronics) containing seven peptides: 
angiotensin II [M+H]+ = 1046.54, angiotensin I [M+H]+ = 
1296.68, substance P [M+H]+ = 1347.74, bombesin [M+H]+ = 
1619.82, ACTH clip (1–17) [M+H]+ = 2093.09, ACTH 
clip (18–39) [M+H]+ = 2465.20, and somatostatin (28) 
[M+H]+ = 3147.47. Internal calibration was performed 
using the CHKtide peptide substrate monoisotopic [M+H]+ = 
2700.60 Th.
Data Analysis
For enzyme characterization, initial rates in both technolo-
gies were determined using time-course experiments under 
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conditions of either excess ATP or CHKtide. The rates were 
plotted against variable substrate concentration and sub-
jected to standard Michaelis-Menten analysis to derive Km 
and Vmax values. Values were normalized for volume and 
protein concentration across the two technologies for com-
parative purposes.
MALDI TOF data processed by the FlexAnalysis 4.0 
software were exported as a .csv file using FlexAnalysis 
Batch Process (Compass 2.0) and further processed in 
Microsoft Excel (Microsoft, Redmond, WA). For peak area 
calculation, the isotopic distribution was taken into account 
by determining a peak area from 2699.4 to 2702.6 m/z for 
the unphosphorylated CHKtide and 2779.8 to 2782.2 m/z 
for the phosphorylated CHKtide.
SIK2 activity was measured by the percent phosphorylation 
(%P) of the CHKtide substrate by the following equation:
Peak Area Phosphorylated Product
Peak Area Phos product Peak A
( )
( ) + rea Substrate( )





×100.
Raw data from the ADP Hunter assay (relative fluorescence 
units [RFU]) were also exported as a comma delimited (.csv) 
file. All subsequent primary single-point screening data pro-
cessing and analysis for both assays were conducted within 
Activity Base version 8.1.2.12 using Activity Base XE 
Runner version 8.1.1 (IDBS, Guilford, UK). Data were nor-
malized and expressed as a percentage effect (PE) value for 
each test compound as follows:
MALDI TOF data:
PE
%P %P
%P %P
test high
low high
=
−
−
×








100
ADP Hunter data:
PE ,=
−
−
×






RFU RFU
RFU RFU
test high
low high
100
where test is the signal associated with the test compound, 
high is the median of the no-effect signal (reaction in pres-
ence of enzyme only), and low is the median of maximum 
effect control signal (reaction in absence of enzyme [bio-
chemical] or presence of staurosporine [MALDI TOF]).
The performance of the assay on each screening plate 
was evaluated using internal controls to determine robust 
signal-to-background (s:b) and robust Z′ values, which 
were calculated as follows:
s:b =
high
low
,
′ = −
×( ) + ×( )
−( )





Z
sMADhigh sMADlow
high
1
3 3
low
,
where high refers to either RFUhigh or %Phigh and low 
corresponds to either RFUlow or %Plow, as appropriate. 
sMADhigh is 1.4826 × median absolute deviation of signal 
associated with the no-effect control, and sMADlow is the 
1.4826 × median absolute deviation of signal calculated for 
the maximum effect control.
All database querying for global data analysis and report 
creation was undertaken using the Dotmatics Browser (ver-
sion 4.9.623.45008-s) and Vortex analysis software (version 
2015.12.46651.25; Dotmatics, Bishop Stortford, UK).
SIK Cellular Assay
The human bone osteosarcoma cell line U2OS (ATCC 
HTB-96) was subcultured and grown in 96-well plates 
(µClear bottom, cat. 655090; Greiner, Stonehouse, UK). 
After 24 h, cells were treated for 1 h with the small-mole-
cule inhibitors staurosporine, HG-9-91-01, KIN112, 
MRT67307, and MRT199665. DMSO at 0.1% and second-
ary antibody-only controls were included on each plate. All 
compounds started at 10 µM and were serially diluted with 
eight replicates per treatment group. Cells were fixed in 4% 
paraformaldehyde in phosphate-buffered saline (PBS) and 
permeabilized with 1% NP-40 in PBS for 10 min each, 
respectively. Following a blocking step with 3% goat serum 
(Sigma) for 45 min, cells were incubated overnight at 4 °C 
with rabbit anti-CRTC3 (1:350; Abcam, Cambridge, UK) 
followed by 1 h with goat anti-rabbit Alexa 488 (1:300; 
Invitrogen, Carlsbad, CA) and 1 µg/mL 4′,6-diamidino-
2-phenylindole (DAPI; Invitrogen). Blocking and antibody 
solutions were made in 1% bovine serum albumin (BSA)–
PBS. Plates were subsequently imaged on a PerkinElmer 
(Coventry, UK) Operetta high-content wide-field fluores-
cence imaging system with a 20× objective and identical 
parameters used for all well and plates: DAPI (em 445 nm), 
Alexa 488 (em 525 nm), and digital phase contrast (ex 740 
nm) with four fields of view imaged per well in an identical 
pattern. Quantification was performed using the Columbus 
database and analysis software. Nuclear intensity of CRTC3 
was quantified via nuclear identification with DAPI, with 
subsequent subtraction of the secondary-only control 
(Alexa 488 signal) from all samples. Results are expressed 
as mean fluorescence intensity ± standard deviation (SD).
Results and Discussion
To screen for inhibitors of the SIK2 kinase, we developed 
and applied three distinct high-throughput assays (Fig. 1): a 
well-established fluorescence-based, enzymatically cou-
pled assay, ADP Hunter; a label-free MALDI TOF assay 
screening for the phosphorylated peptide substrate; and a 
cell-based assay using the nuclear translocation to the SIK 
substrate CRTC3 in response to SIK inhibition. For the in 
vitro kinase assays, human, recombinant full-length SIK2 
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was used. We chose two readily available synthetic peptides 
as substrates for SIKs: NUAK peptide, which is derived 
from NUAK2, a stress-activated kinase from the LKB1 sig-
naling pathway,23 and CHKtide, a peptide derived from the 
CHK1 protein kinase involved in the DNA repair pathway, 
which was recently identified in a kinase screen to be a 
good SIK substrate (unpublished data).
Development of a MALDI-TOF Assay  
for SIK2 Kinase
First, we optimized MALDI TOF assay conditions for ana-
lyzing a peptide substrate. The choice of matrix and spot-
ting technique often has strong effects on the MALDI-MS 
analysis, and there are many matrices commercially 
Figure 1. Workflows to identify salt-inducible kinase (SIK) kinase inhibitors. (A) The biochemical kinase assay was performed using 
ADP Hunter, which uses an enzyme-coupled reaction that produces a red-shifted fluorescence signal that is directly proportional to 
the amount of adenosine diphosphate (ADP) produced by the kinase reaction. (B) For the matrix-assisted laser desorption/ionization 
time-of-flight (MALDI TOF) assay, enzyme reactions were performed in 384-well format with an XRD liquid handler. Samples 
were spotted onto 1536-anchorChip targets using a Mosquito liquid handling robot and analyzed on a Rapiflex mass spectrometer. 
(C) For the fluorescence assay, 15000 U2OS cells per well were treated with inhibitors for 1 h in a 96-well format. Cell were 
fixed, permeabilized, blocked, and incubated with DAPI and an antibody against CRTC3. CRTC3 translocation was analyzed on a 
PerkinElmer Operetta system. ATP, adenosine triphosphate; MALDI TOF, matrix-assisted laser desorption/ionization time-of-flight.
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available. Optimization for these specific peptides showed 
best results when spotted with CHCA in 50% acetonitrile, 
0.1% TFA, and spotting 200-nL sample by a dried droplet 
method23 using a Mosquito nanoliter dispenser, which 
allowed uniform deposition onto the target and matrix. The 
total time taken to spot a full 1536 target was ~30 min, 
which is comparable to other MALDI TOF assay spotting 
times.22
We next tested which of the two substrates performed 
best. The majority of peptides ionize well by MALDI, but it 
has been shown in the past that ionization efficiency is 
dependent on the gas-phase basicity of peptides.24,25 Thus, 
arginine- and lysine-rich peptides tend to have better 
responses, and therefore we expected that the CHKtide sub-
strate would perform better as it contains more basic resi-
dues that are also more distributed over the whole peptide 
sequence. Both peptides were tested for sensitivity, with 
CHKtide indeed proving to perform better with a detection 
limit of 1 fmol on target with good signal to noise (Fig. 2A) 
compared to the NUAK peptide (Suppl. Fig. S1), which 
was also detectable at 1 fmol but exhibited a sevenfold 
lower signal to noise. Both peptides formed only minimal 
salt adducts and oxidized species; therefore, CHKtide was 
chosen to be the substrate of choice for this assay.
With the peptide substrate and spotting technique estab-
lished, the enzymatic reaction was assessed for detection of 
the phosphorylated product, as well as the reaction kinetics. 
Many buffers of biochemical assays contain components 
that are not considered “MS-friendly” as they suppress ion-
ization of the analytes. MALDI TOF has a low tolerance for 
some salts such as NaCl, as it often leads to adduct forma-
tion, thus making interpretation and quantification of pep-
tide spectra difficult.26 We therefore modified established 
kinase assay buffers to be more compatible with MALDI 
TOF, guided by a recent investigation into MALDI-MS–
friendly buffers.19 Initial experiments in the ADP Hunter 
assay showed that the removal of NaCl from the assay buf-
fer did reduce the signal window but did not alter the rank 
order of inhibitors. We therefore removed NaCl from the 
assay buffer of the MALDI assay. Final assay conditions 
gave a robust and reproducible response of both the phos-
phorylated and unphosphorylated peptide, as well as being 
comparable with the conventional ADP Hunter assay that is 
performed in-house.
Figure 2. Matrix-assisted laser desorption/ionization time-of-flight (MALDI TOF) salt-inducible kinase (SIK) kinase assay 
specifications. (A) The MALDI TOF spectra of CHKtide in a dilution series. The assay is very sensitive, with 1 fmol still showing high 
signal to noise. (B) Linearity of MALDI TOF SIK kinase assay. The assay is linear between 10 and 50 min and over a peptide occupancy 
of ~15% to 75%. (C, D) Enzymatic constants determined by MALDI TOF mass spectrometry for CHKtide (C) and adenosine 
triphosphate (D) for SIK2. (E) IC50 dose-response curves for five inhibitors against SIK2 as determined by the MALDI TOF assay.
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Using the MALDI TOF assay, we determined that the 
phosphorylation of CHKtide through SIK2 (Fig. 2B) was 
linear up to 60 min between ~15% and 75% occupancy. 
From these data, an optimal point of 30 min was chosen to 
quench the reaction, thus allowing a conversion of approxi-
mately 50% of the substrate peptide to its phosphorylated 
equivalent. When comparing ADP Hunter and MALDI 
TOF assay enzyme concentrations, similar final enzyme 
concentrations were used. However, the MALDI TOF assay 
uses fourfold less enzyme due to the reduction in assay vol-
ume. Equally, peptide substrate consumption of the MALDI 
assay is up to 300 times lower in concentration and 10 times 
lower in volume, mostly due to the high sensitivity of the 
mass spectrometer.
We further characterized enzymatic constants for CHKtide 
(Fig. 2C) and ATP (Fig. 2D) using the MALDI-TOF assay. 
Both the CHKtide and ATP Km constants were very similar 
for SIK2 and comparable to the Km constants determined in 
the ADP Hunter assay.
Furthermore, we determined for SIK2 a 15-point 
dose-response curves for five known inhibitors (Fig. 2E). 
Staurosporine is a well-known, broad, kinase inhibitor with 
a high potency, whereas HG-9-91-01, MRT199665, 
MRT67307, and KIN112 are all previously described as tar-
geting SIKs at a nanomolar concentration, with HG-9-91-
01 being the most potent of the four.4 These inhibitors were 
chosen as all five are ATP competitive, which reflects the 
small molecular library of ATP mimetics that was selected 
for the screen. Overall, the IC50 values were all in the low 
nanomolar range and about 0.5 to 1 order of magnitude 
higher potency than published biochemical assays,4 sug-
gesting a specific trend in the MS-based assay (Suppl. Fig. 
S2 and Suppl. Table S2). However, this is not unexpected 
as previous IC50 values were determined by less direct 
measurements, such as IL-10 messenger RNA (mRNA) 
induction or cell-based methods. In cells, a higher ATP con-
centration and the presence of other potential targets such as 
AMPKs and a number of protein tyrosine kinases, cellular 
penetration of the compound, and inclusion of high concen-
trations of proteins that may bind to compound could con-
tribute to differences seen for the inhibitor potencies. 
Staurosporine, which serves as a control, appears signifi-
cantly more potent than the four other control inhibitors 
(Suppl. Fig. S2 and Fig. 2E), and we observe a poorer slope 
fit, thus suggesting that other factors such as tight-binding 
could be causing an overestimation in the potency of stau-
rosporine. This could be a result of the IC50 value being near 
or below the SIK2 concentration in the assay, which would 
produce a tight-binding condition and therefore underrepre-
sent the true potency of the inhibitor. Comparison of the 
four other control inhibitors leads us to believe that the ADP 
Hunter and MALDI-TOF assay have similar biochemical 
pharmacology.
MALDI TOF SIK2 Assay Is Comparable to an 
ADP Hunter Assay
Next, we screened the DDU small-molecule kinase library 
against SIK2 using both the MALDI TOF assay and the 
ADP Hunter assay. This library contains 2648 commer-
cially available ATP mimetics describing a diverse region of 
kinase pharmacophore space, consisting of nine 384-well 
assay plates. Both assays were demonstrated to be robust 
methods for screening, with calculated mean robust Z′ and 
robust s:b values (Table 1).
The output of both screens for SIK2, expressed as percent-
age effect for MALDI TOF (Fig. 3A) and ADP Hunter (Suppl. 
Fig. S3), exhibited a normal distribution, with calculated mean 
percentage effects of 2.3 (MALDI TOF) and 7.6 (ADP Hunter) 
for SIK2. Standard deviations of the whole screening data set 
were comparable with 20.6% (MALDI TOF) and 14.6% (ADP 
Hunter) effect. For both screens, compounds producing a sta-
tistically significant effect were defined as those producing a 
percentage effect of greater than or equal to mean effect ± 3 SD 
of the whole screening data set. In addition, the number of 
compounds producing percentage effect greater than 40% 
(Fig. 3B and Suppl. Fig. S4) was also determined for each 
assay. A summary of the number of hit compounds is summa-
rized in Table 2.
As expected for single-shot screens, the number of hits 
was not identical for the two screens, but they did correlate 
(R2 = 0.44) between the percentage effects measured for 
compounds producing greater than 40% effect in the two 
assays (Fig. 3D). With further replicates, we would expect a 
tighter correlation between the hits of the two assays. Eighty 
percent of the ADP Hunter assay hits (PE >40%; 59 com-
pounds) were identified in both screens (28 with PE >3 SD). 
There are also 16 hits that were only identified in the ADP 
Hunter assay and a significant number of hits (45) that were 
only present in the MALDI TOF assay (Fig. 3C), suggesting 
that direct analysis of the peptide product might produce addi-
tional hits compared to the indirect ADP assay. Moreover, nine 
compounds appeared to increase the kinase reaction rate 
that were not identified in the ADP Hunter assay. These hits 
appeared to be genuinely increasing the product formation 
(Suppl. Fig. S5), and more future work will be needed to 
characterize the differences between the ADP Hunter and 
the MALDI TOF assays.
Table 1. Robustness of SIK2 Assays.
SIK2 Assay Robust Z′ Robust s:b
MALDI TOF 0.5 3.0
ADP Hunter 0.9 2.8
MALDI TOF, matrix-assisted laser desorption/ionization time-of-flight; 
s:b, signal to background; SIK2, salt-inducible kinase 2.
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Cellular SIK Inhibition Screen
To take these compounds further and screen SIK kinase activ-
ity in cells, we developed a fluorescence-based assay that was 
built on the fact that CRTC3, a nuclear coactivator for the tran-
scription factor CREB, translocates into the nucleus when SIK 
kinases are inactivated. This is driven by dephosphorylation of 
four serines that are targeted by SIKs. This nuclear transloca-
tion is essential for activating the transcriptional program for 
IL-10 production and polarization toward regulatory-like, anti-
inflammatory macrophages.4,6,26
Human U2OS cells were treated for 1 h with inhibitors, 
cells were fixed, and nuclear CRTC3 translocation was 
analyzed by fluorescence-labeled antibody staining on a 
high-throughput fluorescence imaging platform (PerkinElmer 
Operetta). The cellular assay showed that nuclear transloca-
tion of CRTC3 is enhanced by SIK inhibition. Comparable 
with our in vitro data, strength of CRTC3 translocation is 
correlated with the potency of the inhibitors. Staurosporine 
and HG 9-91-01 are the most potent of the inhibitors com-
pared to DMSO, showing a very dense nuclear localization 
of CRTC3 (Fig. 4A). Kin112 is not as potent, and although 
MRT67307 does induce localization, this is with much 
greater variation versus the other compounds. MRT199665 
is the least potent of all the inhibitors tested (Fig. 4B). These 
data show that this is a useful platform to differentiate 
Figure 3. Comparison between biochemical and matrix-assisted laser desorption/ionization time-of-flight (MALDI TOF) salt-
inducible kinase 2 (SIK2) assay. (A) Blot showing significant hits (>40% inhibition, in red) of the MALDI TOF assay. Data also show 
some apparent activators (<–50% effect). (B) Data distribution of the MALDI TOF SIK2 kinase assay shows a normal distribution. 
(C) Comparison of percentage inhibition for all compounds tested between the biochemical ADP Hunter assay and the MALDI TOF 
assay. (D) Comparison of “hits” (>40% inhibition) from both biochemical ADP Hunter assay and MALDI TOF SIK2 assay showing high 
correlation between the two assays.
Table 2. Number of Compound Hits.
SIK2 Assay PE ≥ Mean ± 3 SD PE ≥40% Unique Hits: PE ≥ Mean ± 3 SD Unique Hits: PE ≥40%
MALDI TOF 45 107 14 45
ADP Hunter 59  79 26 16
MALDI TOF, matrix-assisted laser desorption/ionization time-of-flight; PE, percentage effect; SIK2, salt-inducible kinase.
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screening hits efficacy for SIK inhibitors at the cellular 
level.
In this article, we compared the output of MALDI TOF 
mass spectrometry to the more established ADP hit Hunter 
technology using SIK enzymes as model kinases and pre-
sented a robust cell-based assay providing a suitable down-
stream compound profiling assay for SIK inhibitors. Both 
the MALDI TOF and ADP Hunter techniques generated 
robust assays suitable for both single-point hit discovery 
and compound profiling. The basic enzyme properties char-
acterized were largely similar as were the hit molecules dis-
covered. In addition, the potency of standard inhibitors was 
closely aligned. These data extend the target families where 
MALDI TOF has been demonstrated to be a suitable plat-
form for drug discovery. While MALDI TOF has a higher 
capital entry cost than the more traditional biochemical 
methods, it has advantages in terms of higher sensitivity, 
leading to a reduction in quantities required of both enzyme 
and substrate. In addition, although not an issue with the 
chemotypes used in this study, we anticipate that high-
throughput MALDI TOF will show less false positives and 
false negatives from compound interference such as auto-
fluorescence or usage of fluorescent tags on substrates. 
Moreover, secondary assays such as ADP Hunter might be 
affected by the compounds themselves. Together, the suite 
of assays and validation described here established a plat-
form for early drug discovery for the SIK kinases.
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